Clinical School Johor Bahru, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Sunway campus, 8 Jalan Masjid Abu Bakar, 80100, Johor Bahru, Johor, Malaysia.
BMC Cardiovasc Disord. 2013 Nov 6;13:97. doi: 10.1186/1471-2261-13-97.
The National Cardiovascular Disease (NCVD) Database Registry represents one of the first prospective, multi-center registries to treat and prevent coronary artery disease (CAD) in Malaysia. Since ethnicity is an important consideration in the occurrence of acute coronary syndrome (ACS) globally, therefore, we aimed to identify the role of ethnicity in the occurrence of ACS among high-risk groups in the Malaysian population.
The NCVD involves more than 15 Ministry of Health (MOH) hospitals nationwide, universities and the National Heart Institute and enrolls patients presenting with ACS [ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) and unstable angina (UA)]. We analyzed ethnic differences across socio-demographic characteristics, hospital medications and invasive therapeutic procedures, treatment of STEMI and in-hospital clinical outcomes.
We enrolled 13,591 patients. The distribution of the NCVD population was as follows: 49.0% Malays, 22.5% Chinese, 23.1% Indians and 5.3% Others (representing other indigenous groups and non-Malaysian nationals). The mean age (SD) of ACS patients at presentation was 59.1 (12.0) years. More than 70% were males. A higher proportion of patients within each ethnic group had more than two coronary risk factors. Malays had higher body mass index (BMI). Chinese had highest rate of hypertension and hyperlipidemia. Indians had higher rate of diabetes mellitus (DM) and family history of premature CAD. Overall, more patients had STEMI than NSTEMI or UA among all ethnic groups. The use of aspirin was more than 94% among all ethnic groups. Utilization rates for elective and emergency percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) were low among all ethnic groups. In STEMI, fibrinolysis (streptokinase) appeared to be the dominant treatment options (>70%) for all ethnic groups. In-hospital mortality rates for STEMI across ethnicity ranges from 8.1% to 10.1% (p = 0.35). Among NSTEMI/UA patients, the rate of in-hospital mortality ranges from 3.7% to 6.5% and Malays recorded the highest in-hospital mortality rate compared to other ethnic groups (p = 0.000). In binary multiple logistic regression analysis, differences across ethnicity in the age and sex-adjusted ORs for in-hospital mortality among STEMI patients was not significant; for NSTEMI/UA patients, Chinese [OR 0.71 (95% CI 0.55, 0.91)] and Indians [OR 0.57 (95% CI 0.43, 0.76)] showed significantly lower risk of in-hospital mortality compared to Malays (reference group).
Risk factor profiles and ACS stratum were significantly different across ethnicity. Despite disparities in risk factors, clinical presentation, medical treatment and invasive management, ethnic differences in the risk of in-hospital mortality was not significant among STEMI patients. However, Chinese and Indians showed significantly lower risk of in-hospital mortality compared to Malays among NSTEMI and UA patients.
国家心血管疾病数据库注册代表了马来西亚首例前瞻性、多中心的冠心病(CAD)治疗和预防登记之一。由于种族是全球急性冠状动脉综合征(ACS)发生的一个重要考虑因素,因此,我们旨在确定种族在马来西亚高危人群中 ACS 发生中的作用。
NCVD 涉及全国 15 家卫生部(MOH)医院、大学和国家心脏研究所,招募出现 ACS [ST 段抬高型心肌梗死(STEMI)、非 ST 段抬高型心肌梗死(NSTEMI)和不稳定型心绞痛(UA)]的患者。我们分析了不同种族在社会人口统计学特征、医院药物和介入治疗、STEMI 治疗以及住院临床结局方面的差异。
我们共纳入了 13591 名患者。NCVD 人群的分布如下:49.0%为马来人,22.5%为华人,23.1%为印度人,5.3%为其他(代表其他土著群体和非马来西亚国民)。ACS 患者就诊时的平均(SD)年龄为 59.1(12.0)岁。超过 70%为男性。每个种族群体中都有更多的患者具有超过两个的冠状动脉风险因素。马来人有更高的体重指数(BMI)。华人的高血压和高血脂患病率最高。印度人患糖尿病(DM)和早发冠心病家族史的比例较高。总体而言,与其他所有种族群体相比,更多的患者出现 STEMI 而非 NSTEMI 或 UA。所有种族群体的阿司匹林使用率均超过 94%。所有种族群体的择期和紧急经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)使用率均较低。在 STEMI 中,纤溶酶(链激酶)似乎是所有种族群体的主要治疗选择(>70%)。在 STEMI 中,不同种族的住院死亡率范围为 8.1%至 10.1%(p=0.35)。在 NSTEMI/UA 患者中,住院死亡率范围为 3.7%至 6.5%,与其他种族群体相比,马来人记录的住院死亡率最高(p=0.000)。在二元多变量逻辑回归分析中,STEMI 患者年龄和性别调整后 OR 中种族之间的差异在住院死亡率方面不显著;对于 NSTEMI/UA 患者,华人[OR 0.71(95%CI 0.55,0.91)]和印度人[OR 0.57(95%CI 0.43,0.76)]与马来人(参考组)相比,住院死亡率风险显著降低。
不同种族的危险因素谱和 ACS 分层有显著差异。尽管危险因素、临床表现、药物治疗和介入管理存在差异,但 STEMI 患者的住院死亡率在种族之间没有显著差异。然而,与马来人相比,华人、印度人 NSTEMI 和 UA 患者的住院死亡率风险显著降低。